We are live on ! Find out more
COGT icon

Cogent Biosciences
COGT

28 hedge funds and large institutions have $186M invested in Cogent Biosciences in 2018 Q1 according to their latest regulatory filings, with 28 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

22.23% more ownership

Funds ownership: 0% → 22.23% (+22%)

Holders
28
Holders Change
+28
Holders Change %
–
% of All Funds
0.64%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.09%
New
28
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
AVAI
Atlas Venture Associates IX
Massachusetts
+$37.3M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$26.8M
3
Fidelity International
Fidelity International
Bermuda
+$12.6M
4
SAM
Sectoral Asset Management
Quebec, Canada
+$12M
5
Jennison Associates
Jennison Associates
New York
+$9.96M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
26
DAFNA Capital Management
California
$88K +$87.8K +1,975 New
FPF
27
FNY Partners Fund
New York
$25K +$25.2K +568 New
CCA
28
Catalyst Capital Advisors
New York
$5K +$4.62K +104 New
1
2

COGT Hedge Fund Activity: Q1 2018 in Review

28 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q1 2018, worth a combined $186M.

Buyers outnumbered sellers: 28 funds opened new COGT positions and 0 closed out — a net gain of 28 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Atlas Venture Associates IX, opening a new position worth an estimated $37.3M.

  • 28 institutional investors held Cogent Biosciences (COGT) as of Q1 2018, up from 0 in Q4 2017.
  • Funds reported $186M of Cogent Biosciences stock for Q1 2018.
  • 28 funds opened new Cogent Biosciences positions in Q1 2018 and 0 closed out, a net change of +28 holders.
  • The largest Cogent Biosciences buyer in Q1 2018 was Atlas Venture Associates IX, an estimated $37.3M added.

Based on aggregated 13F filings for Q1 2018.